GlassScriptPhysician profile
Naveen N Sikka
NPI 1912075441
$104,926.76
in general payments reported to CMS, 2019-2025
46 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,904 · 2020: $6,642 · 2021: $13K · 2022: $18K · 2023: $34K · 2024: $18K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $13K · Consulting Fee: $4,507 · Travel and Lodging: $2,161 · Education: $74.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,626.25 |
| Food and Beverage | $13,435.27 |
| Consulting Fee | $4,507.00 |
| Travel and Lodging | $2,161.22 |
| Education | $74.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $62,457.73 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $20,980.43 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genentech USA, INC. | $5,389.86 | 2019-2025 | Xolair, Ocrevus |
| Genzyme Corporation | $3,004.18 | 2019-2025 | |
| Amgen INC. | $2,471.59 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,711.26 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,456.47 | 2020-2025 | Hyqvia, Takhzyro, Vpriv |
| Tersera Therapeutics LLC | $858.64 | 2023-2025 | Quzyttir |
| Biocryst US Sales Co., LLC | $789.46 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $730.49 | 2020-2025 | |
| Grifols USA, LLC | $566.80 | 2019-2025 | Gamunex-C, Xembify |
| Teva Pharmaceuticals USA, INC. | $470.15 | 2019-2023 | |
| Octapharma USA, INC. | $451.33 | 2021-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Csl Behring | $359.39 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Pfizer INC. | $310.19 | 2019-2024 |
Show all 45 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Sikka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.